Displaying 1 - 10 of 241
Alternative Name: 11b-methyl-19-nortestosterone 17b-dodecylcarbonate (11b-MNTDC)
User: Male
Hormonal: Yes
Delivery Method: Injectable, Oral
Developer: BIOQUAL, Inc.
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shandong Provincial Institute, China, Technology for Family Planning, China
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Smaller/Nulliparous Copper IUD, Liberté TT380 Short, Micro T
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
Alternative Name: Abhydrolase Domain Containing 2, 2-Arachidonoylglycerol Hydrolase, Monoacylglycerol Lipase ABHD2, Lung Alpha/Beta Hydrolase 2, Protein PHPS1-2, LABH2, Alpha/Beta Hydrolase Domain Containing Protein 2
Target
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: Acrosomal Vesicle Protein 1, Acrosomal Protein SP-10, Sperm Protein 10, D11S4365, SPACA2, SP-10
Target
User: Female
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: GnRH II Receptor Antagonists
Hormonal: Yes
Developer: CICRR, San Antonio, CONRAD
Development Stage: Compound ID/Selection
Development Phase: Discovery and Early Development
Alternative Name: ADAM Metallopeptidase Domain 2, Fertilin β, Cancer/Testis Antigen 15, Disintegrin And Metalloproteinase Domain-Containing Protein 2, PH30-Beta, FTNB, CT15, PH30, EC 3.4.24, PH-30b, CRYN1, CRYN2, PH-30
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: Androglobin, Calpain-7-Like Protein, C6orf103, Chromosome 6 Open Reading Frame 103, CAPN16, CAPN7L
Target
User: Female, Male
Hormonal: No
Development Stage: Target Identification
Development Phase: Discovery and Early Development
Alternative Name: AF-2364
User: Female, Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Injectable, Oral, Other
Developer: Population Council
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: Inhibitors of Testicular Retinoic Acid Biosynthesis
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Oral
Developer: University of Washington, University of Minnesota
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 41 - 50 of 68
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Microchips Biotech, Inc.
Development Stage: Prototype Development
Target
User: Male
Hormonal: No
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Target Validation
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Washington University
Development Stage: Compound ID/Selection
Alternative Name: Lavax Vaginal Suppository
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Developer: Lavax
Development Stage: Lead Optimization
User: Male
Hormonal: No
Delivery Method: Oral
Developer: North Shore University Hospital in New York
Development Stage: Lead Optimization
Alternative Name: Nomegestrol acetate (NOMAC) vaginal ring
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Developer: Merck
Development Stage: Prototype Development
User: Female, Male
Duration Type: Short-acting, Pericoital
Delivery Method: Injectable, Vaginal, Other, Other
Development Stage: Lead Optimization
User: Male
Hormonal: Yes
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Innolytics LLC
Development Stage: Lead Optimization
PC6
Alternative Name: Proprotein convertase 6
Target
Hormonal: No
Developer: CONRAD, Prince Henry's Institute of Medical Research, Australia
Development Stage: Target Validation

Pages

Displaying 51 - 60 of 122
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: ContraMed, LLC
Development Stage: Phase II
Alternative Name: Pericoital LNG gel
User: Female
Hormonal: Yes
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Population Council
Development Stage: Phase I
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Injectable
Developer: WHO HRP, CONRAD, NICHD
Development Stage: Phase I
Alternative Name: Twirla; AG200-15; Levonorgestrel + ethinyl estradiol patch
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Agile Therapeutics
Development Stage: Phase III
Alternative Name: Levonorgestrel Gastric Resident Dosage Form, Levonorgestrel Gastric Retentive Dosage Form
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Lyndra Therapeutics, Massachusetts Institute of Technology
Development Stage: Pre-clinical
Alternative Name: Levonorgestrel (LNG) Intracervical Device (ICD)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Vaginal, Other
Developer: University of Helsinki, Population Council
Development Stage: Phase I
Alternative Name: Levonorgestrel (LNG)-only patch; AG890
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Agile Therapeutics
Development Stage: Phase II
Alternative Name: One-year LNG Single Rod Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: CONRAD, FEI Technologies
Development Stage: Phase I
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Injectable, Subdermal
Developer: Orbis Biosciences
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Injectable
Developer: FHI 360
Development Stage: Phase I

Pages

Displaying 1 - 10 of 51
Alternative Name: Smaller/Nulliparous Copper IUD, Liberté TT380 Short, Micro T
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: SRA/WHO PQ Approved
Alternative Name: Nestorone + Ethinyl Estradiol One-Year Contraceptive Vaginal Ring, NES + EE Vaginal Ring
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Vaginal Ring
Developer: Population Council, NICHD, WHO, USAID, NIH, Bill & Melinda Gates Foundation, Avis and Clifford Barrus Medical Foundation
Development Stage: SRA/WHO PQ Approved
Alternative Name: SILCS Diaphragm
User: Female
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Barrier
Developer: PATH, CONRAD, SILCS, Inc., Kessel Marketing & Vertriebs GmbH
Development Stage: SRA/WHO PQ Approved
Alternative Name: Saheli; Ormeloxifene
User: Female
Hormonal: No
Duration Type: Short-acting, Emergency
Delivery Method: Oral
Developer: Central Drug Research Institute, India, HLL Lifecare Limited
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Chongqing Medical Equipment Factory Co., Ltd.
Development Stage: Marketed
Alternative Name: Nanocomposite Copper (Cu) IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Tongji Medical College at Huazhong University of Science and Technology
Development Stage: Marketed
Alternative Name: l'Amour®; Jeitosa®
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Cupid Ltd.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Cupid Ltd.
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Concept Foundation, Sun Pharmaceuticals, India, WHO HRP, PT. Tunggal Idaman Abdi
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Injectable
Developer: DKT International, PT Harsen
Development Stage: Marketed

Pages

CSV